Drug prescriptions after acute myocardial infarction: Dosage, compliance, and persistence

Simpson, Ewurabena; Beck, Christine A.; Richard, Hugues; Eisenberg, Mark J.; Pilote, Louise

doi:10.1067/mhj.2003.143

Cited by 91 publications

(65 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, a delay in statin therapy until several months after hospital discharge may be associated with poorer long-term adherence and may result in fewer patients achieving target low-density lipoprotein levels. [17][18][19][20] Moreover, in the present analysis, no statistically significant reduction from statin therapy was seen until 6 years after discharge. This may be related to the development of saphenous vein graft atherosclerosis and occlusion, a process that, although slowed by statin therapy, 7-9 typically manifests clinically 5 to 10 years after CABG.…”

Section: Kulik Et Al Statins and Outcomes After Cabgmentioning

confidence: 63%

Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery

et al. 2008

View full text Add to dashboard Cite

Background-The benefits of statins have been demonstrated for patients with a remote history of coronary artery bypass grafting (CABG); however, no investigation to date has evaluated whether initiation of statin therapy in the early months after surgery improves clinical outcomes. Methods and Results-A retrospective cohort of 7503 Medicare patients Ն65 years of age who underwent CABG (1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003) was assembled by use of linked hospital and pharmacy claims data. Rates of all-cause mortality and major adverse cardiovascular events were compared between patients who were (nϭ1745) and were not (nϭ5788) prescribed statins within 1 month of CABG discharge. Additional analyses evaluated the impact of statin initiation between 1 and 6 months after surgery. Multivariable and propensity score analysis demonstrated that statin use within 1 month of CABG discharge independently reduced the risk of all-cause mortality (adjusted hazard ratio 0.82, 95% confidence interval 0.72 to 0.94) compared with no statin use. Similarly, statin use within 1 month of CABG discharge independently reduced the risk of major adverse cardiovascular events (adjusted hazard ratio 0.89, 95% confidence interval 0.81 to 0.98). Initiation of statin therapy between 1 and 6 months after CABG discharge was also associated with reductions in major adverse cardiovascular events and mortality; however, outcome rates between early (Յ1 month after CABG) and delayed (1 to 6 months after CABG) statin initiation were not significantly different. Conclusions-Statin therapy initiated in the early months after hospital discharge independently reduces all-cause mortality and major adverse cardiovascular events after CABG. These findings validate the widespread practice of prescribing long-term statin therapy after CABG. (Circulation. 2008;118:1785-1792.)

show abstract

Section: Kulik Et Al Statins and Outcomes After Cabgmentioning

confidence: 63%

Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Furthermore, 40 % of participants reported having received clinician advice regarding diet/physical activity. These findings were supported by Simpson et al (2003) who analyzed drug adherence in 14,057 elderly (>65 years) patients after acute myocardial infarction. High 1-year compliance rates and high persistence rates were found.…”

Section: Thrombophilia/factor V Leidenmentioning

confidence: 63%

Patient compliance based on genetic medicine: a literature review

Schneider

Schmidtke

2013

J Community Genet

View full text Add to dashboard Cite

For this literature review, medical literature data bases were searched for studies on patient compliance after genetic risk assessment. The review focused on conditions where secondary or tertiary preventive options exist, namely cancer syndromes (BRCA-related cancer, HNPCC/colon cancer), hemochromatosis, thrombophilia, smoking cessation, and obesity. As a counterpart, patient compliance was assessed regarding medication adherence and medical advice in some of the most epidemiologically important conditions (including high blood pressure, metabolic syndrome, and coronary heart disease) after receiving medical advice based on nongenetic risk information or a combination of genetic and nongenetic risk information. In the majority of studies based on genetic risk assessments, patients were confronted with predictive rather than diagnostic genetic profiles. Most of the studies started from a knowledge base around 10 years ago when DNA testing was at an early stage, limited in scope and specificity, and costly. The major result is that overall compliance of patients after receiving a high-risk estimate from genetic testing for a given condition is high. However, significant behavior change does not take place just because the analyte is "genetic." Many more factors play a role in the complex process of behavioral tuning. Without adequate counseling and guidance, patients may interpret risk estimates of predictive genetic testing with an increase in fear and anxiety.

show abstract

“…Canadian studies have reported ASA and antiplatelet therapy use to be 25% to 37% in patients with a history of CVD and/or diabetes, and as 60% to 64% in patients 90 days after an MI (34,35). Similarly, statin use has been reported to be 25% to 29% in patients with a history of CVD and/or diabetes, and 21% to 43% after an MI (35)(36)(37)(38). Finally, use of ACEI has been reported to be 50% to 60% in patients with a history of CVD and/or diabetes, and 36% to 68% after an MI (34)(35)(36)38).…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, statin use has been reported to be 25% to 29% in patients with a history of CVD and/or diabetes, and 21% to 43% after an MI (35)(36)(37)(38). Finally, use of ACEI has been reported to be 50% to 60% in patients with a history of CVD and/or diabetes, and 36% to 68% after an MI (34)(35)(36)38). Overall, the VP Registry appears to have higher use of statin and ASA, while ACEI use is more representative of actual practice.…”

Section: Discussionmentioning

confidence: 99%